Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis.
复制标题
肝细胞癌、胆管癌和肝硬化中前列腺特异性膜抗原的表达
DOI：
10.3748/wjg.v26.i48.7664
复制
发表时间：
2020-12-28
影响因子：
4.3
通讯作者：
Zhu XH
中科院分区：
文献类型：
--
作者：
Chen LX;Zou SJ;Li D;Zhou JY;Cheng ZT;Zhao J;Zhu YL;Kuang D;Zhu XH
背景原发性肝癌包括三种亚型：肝细胞癌（HCC）、肝内胆管细胞癌（CCA）和混合型肝细胞癌。原发性肝癌患者预后差，死亡率高，因此早期发现肝癌和改善转移管理是降低肝癌死亡人数的关键策略。前列腺特异性膜抗原（PSMA）表达的肿瘤相关的新生血管的非前列腺恶性肿瘤，包括肝癌最近已被报道，但确凿的证据PSMA表达的基础上的肝癌的病理类型仍然有限。目的研究前列腺特异性抗原（PSMA）在肝细胞癌（HCC）、癌前病变（CCA）和肝硬化中的表达.方法回顾性分析同济医院病理科446例福尔马林固定石蜡包埋（FFPE）肝肿瘤和肝硬化组织标本。采用免疫组化法检测446例FFPE肝活检标本（213例HCC、203例CCA和30例肝硬化）中PSMA的表达。分别分析肿瘤区室和相关的新生血管内皮。PSMA表达由两名认证病理学家检查，最终结果以4分评分系统（0 - 3分）表示。PSMA表达与临床病理信息之间的相关性也进行了评估。结果PSMA主要表达于肿瘤相关的新生血管内皮。PSMA在HCC中的阳性表达率明显高于CCA（86.8%vs79.3%，P = 0.001），而在肝硬化中仅为6.6%（P = 0.000）。HCC患者的PSMA染色3分率高于CCA患者（89/213，41.8% vs 35/203，17.2%; P = 0.001）。PSMA表达与HCC和CCA的分期、分级呈正相关。在两种肝癌亚型中，III-V期疾病中的PSMA+病例多于I期和II期。PSMA高染色强度在高级别和晚期肝癌中更常见。在两种肿瘤亚型中，PSMA表达与性别、年龄、地区、甲胎蛋白、B型肝炎表面抗原或肿瘤大小均无显著相关性。结论新生血管PSMA可能是鉴别HCC与肝硬化的一个有前景的标志物，也可能是HCC抗肿瘤血管生成治疗的一个预后指标。
BACKGROUND Primary liver cancer includes three subtypes: Hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (CCA), and combined hepatocellular carcinoma. Patients with primary liver cancer experienced poor prognosis and high mortality, so early detection of liver cancer and improved management of metastases are both key strategies to reduce the death toll from liver cancer. Prostate-specific membrane antigen (PSMA) expression in the tumor-associated neovasculature of nonprostate malignancies including liver cancer has been reported recently, but conclusive evidence of PSMA expression based on the pathological type of liver cancer remains limited. AIM To study the expression of PSMA in HCC, CCA, and liver cirrhosis. METHODS A total of 446 formalin-fixed paraffin-embedded (FFPE) liver tumor and liver cirrhosis tissue samples were obtained retrospectively from the Pathology Department of Tongji Hospital. Immunohistochemistry was used to detect PSMA expression in these 446 FFPE liver biopsy specimens (213 HCC, 203 CCA, and 30 liver cirrhosis). The tumor compartment and the associated neovascular endothelium were separately analyzed. PSMA expression was examined by two certified pathologists, and the final results were presented in a 4-point scoring system (0-3 points). Correlation between PSMA expression and clinicopathological information was also assessed. RESULTS PSMA was expressed primarily in the neovascular endothelium associated with tumors. The positive rate of PSMA staining in HCC was significantly higher than that in CCA (86.8% vs 79.3%; P = 0.001) but was only 6.6% in liver cirrhosis (P = 0.000). HCC cases had more 3-score PSMA staining than CCA had (89/213, 41.8% vs 35/203, 17.2%; P = 0.001). PSMA expression correlated positively with the stage and grade of HCC and CCA. In both liver cancer subtypes, there were more PSMA+ cases in stages III–V diseases than in stages I and II. High staining intensity of PSMA was more frequently observed in liver cancers at high grade and advanced stage. There was no significant association of PSMA expression with sex, age, region, α-fetoprotein, hepatitis B surface antigen, or tumor size in both tumor subtypes. CONCLUSION Neovascular PSMA may be a promising marker to differentiate HCC from liver cirrhosis and a prognostic marker for anti-tumor angiogenesis therapy for HCC.
登录
查看更多内容
影响因子：
5.8
作者：
Nomura N;Pastorino S;Jiang P;Lambert G;Crawford JR;Gymnopoulos M;Piccioni D;Juarez T;Pingle SC;Makale M;Kesari S
通讯作者：
Kesari S
影响因子：
3.2
作者：
Ahmadzadehfar H;Rahbar K;Kürpig S;Bögemann M;Claesener M;Eppard E;Gärtner F;Rogenhofer S;Schäfers M;Essler M
通讯作者：
Essler M
影响因子：
7.5
作者：
Haffner, Michael C.;Laimer, Johannes;Bander, Neil H.
通讯作者：
Bander, Neil H.
影响因子：
9.3
作者：
Nimmagadda, Sridhar;Pullambhatla, Mrudula;Pomper, Martin G.
通讯作者：
Pomper, Martin G.
影响因子：
2.6
作者：
Kinoshita, Y;Kuratsukuri, K;Haas, GP
通讯作者：
Haas, GP